Maven Securities LTD Acquires Shares of 65,000 Revolution Medicines, Inc. (NASDAQ:RVMD)

Maven Securities LTD bought a new position in shares of Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 65,000 shares of the company's stock, valued at approximately $2,843,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Boxer Capital Management LLC acquired a new position in Revolution Medicines in the 4th quarter valued at about $187,184,000. Janus Henderson Group PLC raised its position in shares of Revolution Medicines by 54.5% in the fourth quarter. Janus Henderson Group PLC now owns 9,483,999 shares of the company's stock valued at $414,777,000 after buying an additional 3,346,755 shares during the last quarter. Vanguard Group Inc. boosted its position in Revolution Medicines by 14.7% during the fourth quarter. Vanguard Group Inc. now owns 17,096,455 shares of the company's stock worth $747,799,000 after acquiring an additional 2,185,082 shares during the last quarter. Farallon Capital Management LLC raised its holdings in Revolution Medicines by 17.1% in the 4th quarter. Farallon Capital Management LLC now owns 13,248,692 shares of the company's stock valued at $579,498,000 after acquiring an additional 1,931,000 shares during the last quarter. Finally, Norges Bank purchased a new position in shares of Revolution Medicines during the 4th quarter worth $76,197,000. Hedge funds and other institutional investors own 94.34% of the company's stock.

Insider Transactions at Revolution Medicines

In other Revolution Medicines news, CFO Jack Anders sold 1,864 shares of the business's stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $72,770.56. Following the completion of the transaction, the chief financial officer now directly owns 115,006 shares of the company's stock, valued at approximately $4,489,834.24. The trade was a 1.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Mark A. Goldsmith sold 11,738 shares of Revolution Medicines stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $458,251.52. Following the completion of the sale, the insider now directly owns 441,564 shares of the company's stock, valued at $17,238,658.56. This trade represents a 2.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 16,660 shares of company stock valued at $650,406. Corporate insiders own 8.00% of the company's stock.

Revolution Medicines Price Performance

NASDAQ RVMD opened at $41.88 on Tuesday. Revolution Medicines, Inc. has a 52-week low of $29.17 and a 52-week high of $62.40. The firm has a market capitalization of $7.80 billion, a price-to-earnings ratio of -11.67 and a beta of 1.11. The company's fifty day moving average is $37.40 and its two-hundred day moving average is $43.36.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.12) by ($0.01). During the same period last year, the business earned ($0.70) earnings per share. As a group, sell-side analysts expect that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $57.00 price objective on shares of Revolution Medicines in a research note on Thursday, May 8th. Stifel Nicolaus reduced their price objective on Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Oppenheimer boosted their target price on Revolution Medicines from $70.00 to $75.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Wedbush restated an "outperform" rating and issued a $67.00 price target on shares of Revolution Medicines in a report on Thursday, May 8th. Finally, Guggenheim decreased their price objective on shares of Revolution Medicines from $87.00 to $80.00 and set a "buy" rating for the company in a research note on Thursday, May 8th. Twelve research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Revolution Medicines currently has an average rating of "Buy" and a consensus target price of $67.17.

Revolution Medicines Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.